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Background: Despite significant advances in staging and therapies, lung cancer remains a major cause of
cancer-related lethality due to its high incidence and recurrence. Clearly, a novel approach is required to
develop new therapies to treat this devastating disease. Recent evidence indicates that tumours contain a small
population of cells known as cancer stem cells (CSCs) that are responsible for tumour maintenance, spreading and
resistant to chemotherapy. The genetic composition of CSCs so far is not fully understood, but manipulation of the
specific genes that maintain their integrity would be beneficial for developing strategies to combat cancer. Therefore,
the goal of this study isto identify the transcriptomic composition and biological functions of CSCs from non-small cell
lung cancer (NSCLC).
Methods: We isolated putative lung CSCs from lung adenocarcinoma cells (A549 and H2170) and normal stem cells
from normal bronchial epithelial cells (PHBEC) on the basis of positive expression of stem cell surface markers (CD166,
CD44, and EpCAM) using fluorescence-activated cell sorting. The isolated cells were then characterised for their
self-renewal characteristics, differentiation capabilities, expression of stem cell transcription factor and in vivo
tumouregenicity. The transcriptomic profiles of putative lung CSCs then were obtained using microarray analysis.
Significantly regulated genes (p < 0.05, fold change (FC) > 2.0) in putative CSCs were identified and further analysed for
their biological functions using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).
Results: The putative lung CSCs phenotypes of CD166+/CD44+ and CD166+/EpCAM+ showed multipotent characteristics
of stem cells, including the ability to differentiate into adipogenic and osteogenic cells, self-renewal, and expression of
stem cell transcription factors such as Sox2 and Oct3/4. Moreover, the cells also shows the in vivo tumouregenicity
characteristic when transplanted into nude mice. Microarray and bioinformatics data analyses revealed that the
putative lung CSCs have molecular signatures of both normal and cancer stem cells and that the most prominent
biological functions are associated with angiogenesis, migration, pro-apoptosis and anti-apoptosis, osteoblast
differentiation, mesenchymal cell differentiation, and mesenchyme development. Additionally, self-renewal pathways
such as the Wnt and hedgehog signalling pathways, cancer pathways, and extracellular matrix (ECM)-receptor
interaction pathways are significantly associated with the putative lung CSCs.
Conclusion: This study revealed that isolated lung CSCs exhibit the characteristics of multipotent stem cells and
that their genetic composition might be valuable for future gene and stem cells therapy for lung cancer.
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Lung cancer is one of the most common malignancies
throughout the world. It accounted for about 16.1 mil-
lion deaths in 2008 and is the leading cause of cancer-
related death [1]. Based on pathological features, lung
cancer is classified into two major groups; small cell lung
carcinoma (SCLC) and non-small cell lung carcinoma
(NSCLC). The majority of lung cancer cases are NSCLC
(80%). NSCLC is less aggressive than SCLC. NSCLC
tends to grow and spread slower than SCLC, which is
fast growing and rapidly spreads to the bloodstream and
other parts of the body. The three main subtypes of
NSCLC are adenocarcinoma, squamous cell carcinoma,
and large-cell carcinoma. The prognosis for patients
with NSCLC remains very poor, with only 15% survival
within 5 years after treatment [2,3]. Moreover, the recur-
rence rate ranges from 35% to 50% among early stage
NSCLC patients: After an apparently successful initial
therapy, development of secondary tumours often leads
to a lethal relapse.
The biological characteristics associated with the ag-
gressive behaviour of cancer cells is driven by a subpop-
ulation of cells within the tumour called cancer stem
cells (CSCs) [4,5]. CSCs were first described in human
hematopoietic cancer, and to date they have been identi-
fied in solid tumours of breast [6], pancreas [7], brain
[8], and colon [9,10] cancers. CSCs can self-renew, initi-
ate tumour development, and differentiate into multiple
cell types [4,11-13], and recent evidence suggests that
these cells play a central role in the progression of ma-
lignant tumours. The CSCs model describes the existence
of a small subpopulation of plastic cells with transdifferen-
tiation potential in tumours. However, recent studies sug-
gest that a major proportion of cells within tumours
maintain stem cell properties and even more differentiated
cells can be transformed into stem-like cells [13,14]. If this
is the case, eradication of CSCs might not be a useful
strategy for the reduction of tumour growth. Therefore, it
is important to understand CSCs biology and identify new
strategies to prevent malignant tumour progression. The
mechanisms that regulate self-renewal of both CSCs and
normal stem cells are thought to be similar [4].
Currently, identification and isolation of CSCs is
largely dependent on the presence of specific cell surface
markers [10,15], although the expression of such markers
depends on various factors (e.g., the differentiation state of
the cells and niche factors). Many of the markers used to
identify CSCs are derived from the surface markers known
to be present on normal hematopoietic or embryonic stem
cells. CD133 has been used as a putative stem cell marker
in glioblastoma [16] and colon cancer [9]; CD34 express-
ing tumour epithelial cells have been used as a marker in
cutaneous cancer [17]; and CD44 expressing cells have
been used as a marker in breast cancer [18]. Moreover,CD26 positive cells are indicative of metastases, invasive-
ness, and chemoresistance in colon cancer, and CD271
positive cells initiate melanoma progression and metasta-
sis [19]. For lung CSCs, CD133 [20], CD166 [21], EpCAM,
CD90, and CD44 [15,22] have been used as markers.
CD133 is a well-described CSCs marker in various types
of cancers, including hematopoietic [23], brain [11], colon
[10], pancreatic [7], and lung [20] cancers. In NSCLC and
SCLC patient samples, CD133+ cells possess tumourigenic
and self-renewal characteristics [20]. However, several stud-
ies suggest that the use of CD133 expression to discrimin-
ate lung CSCs is overstated. For example, some CD133−
lung cancer cells also possess the ability to self-renew and
generate the formation of xenograft when transplanted into
recipient mice [24]. Unlike in gliomas, where CD133 is a
more established cancer stem cell marker, CD133 expres-
sion in lung cancer is not associated with patient prognosis
[25-27]. Moreover, in many lung cancer samples, CD133 is
not detected [26-28]. Recently, few scientists have ques-
tioned the use of CD133 as a selective CSCs marker in
other solid tumour types, citing cases where CD133ˉ cells
also possess the capacity for self-renewal and cancer initi-
ation [29,30]. Based on these data, we exclude CD133 in
this study and focus only on CD166, CD44, and EpCAM.
The goal of this study is to identify and characterise
the CSCs population in human NSCLC using CD166,
CD44, and EpCAM as markers. We also conducted
transcriptomic profiling of the isolated CSCs to deter-
mine how the transcriptome is involved in the signaling
pathways specific to the CSCs of lung cancer.
Methods
Cell lines
The human lung cancer cell lines A549 (lung carcinoma)
and H2170 (squamous cell carcinoma) and the normal
primary human bronchial/tracheal epithelium (PHBEC)
cell line were purchased from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA).
Cell culture
The cancer cell lines were cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. Cells were incu-
bated in a humidified incubator at 37°C and 5% CO2.
Cells were maintained in 75 cm2 tissue culture flasks
and harvested by 0.25% trypsin-EDTA treatment when
they reached 80% confluency. Unless specified, all re-
agents were obtained from Gibco (Life Technologies,
Foster City, CA, USA).
PHBECs were cultured in specific airway epithelial cell
medium purchased from ATCC. The medium consists of
airway epithelial cell basal medium (PCS-300-030) supple-
mented with the bronchial/tracheal epithelial growth kit
(PCS-300-040), gentamicin-amphoterin B solution (PCS-
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(PCS-999-002), and phenol red (PCS-999-001). The cells
were incubated in a humidified incubator at 37°C and 5%
CO2. Cells were maintained in 75 cm
2 tissue culture flasks
and harvested using 0.05% Trypsin-EDTA when they
reached 80% confluence.
Isolation of putative CSCs and normal stem cells
The lung cancer cells and normal cells were detached
with trypsin and washed with phosphate buffer solution
(PBS) containing 2% FBS (PBS/2% FBS). The cell sus-
pensions were then labelled with antibodies CD44-FITC
(Clone: L178; Isotype: Mouse IgG1, κ), CD166-PE (Clone:
3A4; Isotype: Mouse IgG1, κ) (BD Biosciences, San Jose,
CA, USA), and EpCAM–FITC (Clone: 158206; Isotype:
Mouse IgG2B; Isotype: Mouse IgG1, κ) (R&D System,
Minneapolis, MN, USA). Briefly, the cells were resus-
pended in 90 μL of PBS/2% FBS. Next, 10 μL of each anti-
body were added to the cell suspensions and incubated for
30 min on ice and in the dark. At the end of the incuba-
tion, unbound antibodies were washed away with PBS.
Each cells pellet was resuspended in 300–500 μL PBS/2%
FBS and filtered through a 40 μm cell strainer to obtain a
single cell suspensions before sorting. The expression of
cancer stem cell markers (CD166, CD44, and EpCAM)
was analysed and populations of cells expressing the
markers were sorted using a fluorescence-activated cell
sorter (FACSAria III, BD Biosciences). The sorting for
each cell population was done in three independent exper-
iments to represent the biological variation.
Adipogenic, chondrogenic, and osteogenic differentiation
in vitro
The putative CSCs were induced to differentiate into dif-
ferent lineages using adipogenic, chondrogenic, and
osteogenic differentiation media (PromoCell, Heidelberg
Germany). Briefly, the putative CSCs were seeded in 24-
well tissue culture plates until the cells reached 80–90%
confluence (for adipogenic differentiation) or 100% con-
fluence (for chondrogenic and osteogenic differentiation).
The initial seeding number was 6 × 104 cells for adipo-
genic and chondrogenic differentiation and 1 × 105 cells
for osteogenic differentiation. Once the cells reached the
required confluency, two sets of triplicate wells were in-
duced to differentiate by replacing the culture medium
with the specific differentiation medium. The remaining
wells containing the normal medium served as the control.
The cells were incubated for 14 days (adipogenic differenti-
ation) and 21 days (chondrogenic and osteogenic differen-
tiation), and the medium was changed every 3 days.
Detection of differentiation in vitro
At the end of the incubation period, the cells were
washed with PBS, fixed with 10% buffered formalin, andstained with a respective staining solution to detect adi-
pocyte, chondrocyte, or osteocyte formation. Formation
of adipocytes was detected by observing intracellular
lipid vesicles stained red by 0.3% Oil Red O (Sigma-
Aldrich, Munich, Germany). After the cells were fixed,
they were incubated with 60% isopropanol at room
temperature for 5 min. The isopropanol was carefully
aspirated, and Oil Red O staining solution was added to
cover the cells. The cells were incubated for 15 min,
washed several times with distilled water, and counter-
stained with a Harris Hematoxylin solution for 1 min.
Lastly, the cells were washed with distilled water and ob-
served under the microscope.
Osteocyte formation was detected by staining calcium
deposits with 2% Alizarin Red S (Sigma-Aldrich). The
fixed cells were incubated with Alizarin Red S staining
solution for 45 min at room temperature in the dark.
The cells were washed four times with distilled water,
and PBS was then added to each well. When observed
under the microscope, extracellular calcium deposits
were stained bright orange-red. Chondrogenic differenti-
ation was detected by staining with Alcian blue staining
solution (Sigma-Aldrich). The fixed cells were incubated
with Alcian blue staining solution overnight at room
temperature in the dark. The cells were washed four
times with distilled water, and PBS then was added to
each well. When observed under the microscope, the
cartilages were stained an intense dark-blue, whereas
other tissue was at most faintly bluish.Colony forming assay
For the colony forming assay, the cells were trypisinised
as described previously. The cells were seeded in 6-well
plates at low density (~200 cells per well) and cultured
for 7 days. The plates were then washed with PBS and
fixed with 10% formalin for 10 min followed by staining
with crystal violet for 30 min. The plates were then
washed with PBS, and images of each well were captured
using an inverted microscope. The experiment was per-
formed in three independent replicates for A549 and
H2170 cells.Sphere forming assay
Isolated putative lung CSCs were cultured in low adher-
ent 35 mm dishes under serum-free conditions and sup-
plemented with 20 ng/ml of epidermal growth factor
(EGF) (Life Technologies, Foster City, CA, USA) 10 ng/ml
of basic fibroblast growth factor (bFGF) (Life Technolo-
gies), and B27 supplement (Life Technologies) for 21 days
according to published protocols [15]. The experiment
was conducted in three independent replicates for A549
and H2170 cells.
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The expression of stem cell transcription factors was de-
tected using two step real time polymerase chain reaction
(RT-PCR) analyses. Initially, total RNA was extracted from
the sorted cells using a Qiagen AllPrep DNA/RNA Isola-
tion Kit (Qiagen) according to the manufacturer’s ins-
tructions. Complementary DNA (cDNA) was synthesized
from 1 μg of total RNA using the Transcriptor First Strand
cDNA Synthesis Kit (Roche Applied Science, Mannheim,
Germany). The random hexamer and anchored-oligo (DT)
primers were used. The RT-PCR reaction was prepared
using SYBR Green I PCR reagents (KAPA Biosystems,
Boston, USA), and the primer for the Sox2, Klf4, c-Myc,
Nanog, Oct 3/4, and GAPDH genes from the Pluripo-
tency Check PCR Primer Set (Clontech Laboratories
Inc, Mountain View, USA) were used (Table 1). The RT-
PCR reaction was performed using the ABI StepOnePlus™
PCR System (Applied Biosystems, Foster City, USA)
under the following procedure: 95 ˚C for 4 min, 40 cycles
of 95 ˚C for 15 sec, 60 ˚C for 30 sec, and 72 ˚C for 30 sec.
Quantification was performed using the comparative Ct
method. The normal stem cell was used as the control
sample, and the GAPDH gene was used as the endogen-
ous control.
In vivo tumourigenicity studies
The ability of the marker-selected cells to initiate in vivo
tumour development was investigated by subcutaneous
transplantation of cells into nude mice. All experiments
were carried out using 4–7 week old female NCR nude
mice (INVIVOS, Perahu Rd, Singapore). Mice were main-
tained in individually ventilated cages (IVC) (Allentown
Inc., NJ, United States). The experiments were approved
by the Universiti Sains Malaysia Animal Ethics Committee
according to the institutional guidelines. For the mouse
xenograft, 2 × 104 cells from parental cells, putative CSCs,
and putative non-CSCs of both A549 and H2170 cell lines
were mixed with matrigel (BD Biosciences) and subcuta-
neously injected into the right flank of the nude mice
(n = 3 for each cell type). Mice were monitored every
2 days between two weeks after inoculation. The mice were








Sox2 GGTTACCTCTTCCTCCCACTCAGleast 1 cm in size. All tumour tissues were collected for
morphological and histological analysis.
Microarray analysis
Total RNA extraction and cDNA synthesis
Total RNA was extracted from up to 1 × 106 CD166+/CD44+
and CD166+/EpCAM+ PHBEC, A549, and H2170 cells
using the Qiagen AllPrep DNA/RNA Isolation Kit (Qiagen)
according to the manufacturer’s protocol. Briefly, the
cells were lysed with lysis buffer and homogenized
using the QIAshredder Homogenizer (Qiagen). Ethanol
(70%) was then added to the homogenized cell lysates,
and the cell lysates were transferred into the RNA spin
column. Total RNA that bound to the spin column was
eluted from the spin column using RNase free water. The
concentration and purity of the extracted RNA were de-
termined using a Nanodrop® ND1000 spectrophotometer,
and the RNA integrity number (RIN) was determined
using the Bioanalyzer 2100 (Agilent Technologies).
ST-cDNA amplification, purification, fragmentation, and
labelling
Total RNA (1.5 μg) was amplified using the Applause™
WT-Amp ST System (Nugen Technologies, Inc., San
Carlos, USA) following the manufacturer’s protocol. The
seven step amplification process produced ST-cDNA,
which was further purified using the MinElute Reaction
Cleanup Kit (Qiagen). The yield and purity of the puri-
fied ST-cDNA were measured using the Nanodrop®
ND1000 spectrophotometer. The A260:A280 ratio must
be > 1.8 and the concentration must be in the range of 2
to 2.5 μg for the ST-cDNA to be hybridised to the array.
The purified ST-cDNA was then fragmented and la-
belled with biotin (Nugen Technologies).
Array hybridisation and scanning
Biotin-labelled fragmented ST-cDNA was hybridised to
oligonucleotide probes on Affymetrix GeneChip® 1.0 ST
arrays and then washed and stained using the GeneChip®
Hybridisation Wash and Stain Kit. For each array,
2–2.5 μg of the fragmented biotin-ST-cDNA were hybri-
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FS450_0007 protocol of the Affymetrix Fluidics Station
FS450. The arrays were scanned with an Affymetrix
Scanner 3000, and data were obtained using the Gene-
Chip® Operating Software. The microarray experiment
was performed using three biological replicates for each
sample.
Data processing and analysis
Microarray data analysis was performed using GeneSpring
GX 7.3.1 software (Agilent Technologies). The CEL file of
each array was normalized to the 50th percentile, and
probes/genes with expressions less than the 50th percent-
ile were excluded. To identify the significantly regulated
genes of putative CSCs, statistical analysis was conducted
by comparing the FC of putative CSCs to its normal
counterparts (Table 2). The probes/genes then were
filtered based on p-value and FC. Probes/genes with
p-value < 0.05 and FC > 2.0 were assumed to be signifi-
cantly regulated. The microarray raw data discussed in
this paper were deposited in the NCBI GEO database
(Accession number: GSE50627).
Microarray validation
The differentially expressed genes identified in the micro-
array analysis were validated by RT-PCR using Taqman®
Gene expression assays (Applied Biosystems) in the ABI
StepOnePlus™ Real-Time PCR machine. The PCR reac-
tions included 1 μL of 20× Taqman® primer, 10 μL of 2×
Taqman® Gene Expression master mix, 2 μL of cDNA
template, and 7 μL of RNase free water. The RT-PCR
thermal profile was obtained using the following proced-
ure: 50°C for 2 min, 95°C for 20 sec, 40 cycles at 95°C for
15 sec and 60°C for 1 min. Table 3 lists the primer se-
quences used. The expression level of each target gene in
the tested experimental condition (putative lung CSCs)
was compared to that of the control condition (PHBEC),
and the data was normalized to GAPDH gene expression.
Functional enrichment analysis
Functional enrichment analysis was performed using
DAVID (http://david.abcc.ncifcrf.gov/) [31,32]. Signifi-
cantly regulated genes (FC > 2; p < 0.05) from each group
were submitted to DAVID. The analysis was started by
clicking on “Start Analysis” on the header, and the gene
list manager panel that appeared was used to performTable 2 Comparison groups in microarray data analysis
conducted using gene spring software
Group number Comparison
1 A549 CD166+/ CD44+ vs. PHBEC CD166+/CD 44+
2 A549 CD166+ /EpCAM+ vs. PHBEC CD166+ /EpCAM+
4 H2170 CD166+ /EpCAM+ vs. PHBEC CD166+ /EpCAM+the analysis step. First, the list of gene IDs was copied
and pasted into box A, an appropriate gene identifier
type (gene list or background) for the input gene ID was
selected, and the submit button was pressed. If DAVID
could not recognize more than 20% of the submitted gene
ID, the submission was redirected to the DAVID Gene ID
Conversion Tool. Once the list of genes was successfully
submitted, the analysis of the list was performed using the
available DAVID analysis tools. These tools include func-
tional annotation tools, gene functional classification
tools, and the gene name batch viewer.
Results
Expression of cancer stem cell markers in NSCLC cells
To identify the subpopulation of putative CSCs in cancer
cell lines, we investigated the expression of three stem
cell surface markers (CD166, CD44, and EpCAM) that
previously were described as prominent CSCs markers in
lung cancer. Expressions of CD166, CD44, and EpCAM
varied among the cell lines. All surface markers except
CD44 were expressed in all cell lines, but they exhibited
different degrees of expression. CD166 was highly
expressed in all cell lines: PHBEC (expressed in 38.7% of
cells), A549 (72.9%), and H2170 (52.6%) (Figure 1).
CD44 expression was detected only in the PHBEC cells
(2.2%) and A549 cells (61.5%) (Figure 1). The expression
of EpCAM differed among the cell lines, with the high-
est expression observed in the H2170 cells (33.8%)
followed by the A549 cells (13.8%) and the PHBEC cells
(4.9%) (Figure 1).
Co-expression of CD166 with CD44 and EpCAM to
identify the subpopulation of NSCLC cells with stem
cell-like properties
To identify a more stringent phenotype for the putative
CSCs population, co-expression of two markers was inves-
tigated. Because the initial analysis using single marker ex-
pression showed that CD166 was the prominent marker
in both cell lines, we evaluated co-expression of CD166
with CD44 and CD166 with EpCAM. In A549 cells, 62.5%
of the cells expressed CD166/CD44 and 9.8% of the cells
Figure 1 Identification of CD166+, CD44+, and EpCAM+ cells in cancer cell lines (A549 and H2170) and the normal bronchial/tracheal
epithelial cell line (PHBEC) by flow cytometry analysis. A subpopulation of CD166+ cells was identified in the PHBEC (38.7%), A549 (72.9%),
and H2170 (52.6%) cell lines. A subpopulation of CD44+ cells was identified in the PHBEC (2.2%) and A549 (61.5%) cell lines, but CD44+ cells were
totally absent in the H2170 cell line. In the PHBEC, A549, and H2170 cell lines, 4.9%, 13.8%, and 33.8%, respectively, were EpCAM+.
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expression of CD166/EpCAM was observed in 3.1% of the
cells (Figure 2). The double positive cells from the A549
and H2170 cell lines were sorted out and defined as puta-
tive lung CSCs. To validate the stemness characteristics of
the putative lung CSCs, we also sorted out the double nega-
tive population (i.e., CD166−/CD44− and CD166−/Ep
CAM−) and called this population putative non-CSCs.
Putative lung CSCs exhibit differentiation potential
The characteristics of the putative CSCs and putative
non-CSCs were assessed by their ability to differentiate
into multilineage cells. The cells were induced to differ-
entiate into adipogenic, osteogenic, and chondrogenic
cells by culturing them in stem cell differentiation media.
Putative CSCs of the A549 and H2170 cell lines were
able to differentiate into adipogenic and osteogenic
lineages (Figure 3). However, the putative non-CSCs
lacked this characteristic (Figure 3). Neither putativeCSCs nor putative non-CSCs of both cells lines could dif-
ferentiate into chondrogenic cells (data are not shown).
Self-renewal ability of putative lung CSCs
Self-renewal capacity is one of the characteristics of stem
cells. The results from the colony formation efficiency
assay show that putative CSCs isolated from the A549
and H2170 cells were able to form colonies (Figure 4).
However, putative non-CSCs isolated from both cell
lines also had the ability to form colonies. We further
validated the self-renewal characteristics of the cells by
performing the sphere forming assay. After being cul-
tured in serum-free medium supplemented with fibro-
blast growth factor (bFGF), epidermal growth factor
(EGF), and B27 supplement, both putative lung CSCs
and putative non-CSCs formed colonies. However, the
colony size and the number of colonies formed differed:
Putative lung CSCs formed more and larger colonies
compared to putative non-CSCs (Figure 4). We concluded
Figure 2 Flow cytometry analysis of co-expression of CD166/CD44 and C166/EpCAM in the normal bronchial/tracheal epithelial cell
line (PHBEC) and cancer cell lines (A549 and H2170). The cells were stained with anti-CD166 PE, anti-CD44 FITC, and anti-EpCAM FITC.
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ability, but the capability is more prominent and higher in
the putative lung CSCs.
Putative lung CSCs exhibit stem cell gene expression
The observation that the putative lung CSCs had the abil-
ity to differentiate into adipogenic and osteogenic cells led
us to investigate whether these cells express stem cell
transcription factors such as Sox2, Oct 3/4, Nanog,
c-Myc, and Klf4. The expression of the genes was detected
using the real-time polymerase chain reaction (RT-PCR)
method, and the relative expression of the genes in puta-
tive CSCs was compared to the expression of the genes in
normal stem cells (PHBEC). Detectable expression levels
of these genes were found in putative CSCs of both cell
lines (Figure 5). In A549 CD166+/CD44+ cells, Sox2 and
Oct4 were up-regulated with FC values of 2.472 and 3.981
respectively. In A549 CD166+/EpCAM+ cells, expressionof Oct3/4 (3.874) and c-Myc (2.619) was also detected.
For H2170 CD166+EpCAM+ cells, expressions of Sox2
(FC = 4.753), Oct4 (17.484), Klf4 (3.017), and c-Myc
(3.213) were up-regulated. The expression of Nanog was
down-regulated in all putative CSCs.
In vivo tumourigenicity properties of putative lung CSCs
The ability of putative lung CSCs to develop tumours
in vivo was investigated by subcutaneous transplantation
of the cells into nude mice. The injected cells from par-
ental, putative lung CSCs, and putative non-CSCs were
able to initiate tumours in vivo, but the tumour sizes
and tumour incidence differed between the treatments
(Figure 6 and Table 4). Putative lung CSCs initiated the
growth of larger tumours compared to parental cells and
putative non-CSCs. In addition, putative lung CSCs
formed tumours in all animals (n = 3), whereas putative
non-CSCs formed tumours in two of the three injected
Figure 3 Adipogenic and osteogenic differentiation potential of putative CSCs from the A549 and H2170 cell lines. (A) Adipogenic
differentiation and (B) osteogenic differentiation of putative lung CSCs and putative non-CSCs.
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lung CSCs also was higher than those of parental and
putative non-CSCs (Figure 6). Therefore, the in vivo
tumourigenicity experiments demonstrated that the pu-
tative lung CSCs were more tumourigenic than the par-
ental and putative non-CSCs.
Transcriptomic profiling of putative lung CSCs using
microarray analysis
The mRNA expression profiles of putative lung CSCs
were measured using Affymetrix Expression Console™
software (Affymetrix, Santa Clara, CA, USA), and the
data were analysed using GeneSpring software version
12.5 (Agilent Technologies, Santa Clara, CA, USA). The
intensity of each array was normalized to the 50th per-
centile of expression, and the significantly regulated
genes were selected using independent t-test statistical
analysis by comparing the data from the putative CSCs
with those from normal lung stem cells. The genes that
had a FC > 2.0 and a p-value < 0.05 were considered to
be significantly regulated. The lists of significantly regulatedgenes are shown in the (Additional file 1: Table S1,
Additional file 2: Table S2, and Additional file 3: Table S3)
for each group. Table 5 summarises the numbers of sig-
nificantly regulated genes for each putative CSC, and
volcano plot analysis was used to visualise the signifi-
cance and the magnitude of the significantly regulated
genes (Figure 7). The number of significantly regulated
genes ranged from 1229 to 1335, and the number of
down-regulated genes was higher than that of up-
regulated genes.
Validation of microarray data by RT-PCR
To verify the expression value of the microarray data,
the original amplified RNA samples used for microarray
analysis were validated for six genes using RT-PCR.
Three of the selected genes were up-regulated and three
were down-regulated. The expression values detected by
both microarray and RT-PCR techniques were plotted as
log2 FC (Figure 7). The Pearson correlation coefficient
test showed that the expression values detected by both
platforms were in agreement (p < 0.05) (Figure 7).
Figure 4 Self-renewal assay of putative CSCs. (A) Colony forming assay of putative CSCs. (B) and (C) show the sphere forming ability of
putative CSCs. The error bar indicate the average +/− standard deviation of three independent experiments.
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genes in putative CSCs
To gain a better understanding of the functions of sig-
nificantly regulated genes in lung CSCs, we conducted
bioinformatics analysis using the Database for Annota-
tion, Visualization, and Integrated Discovery (DAVID)
programme. We looked at the gene ontology (GO) terms
for biological function and the Kyoto Encyclopaedia of
Genes and Genomes (KEGG) pathways that are associ-
ated with the CSCs gene list. Up- and down-regulated
genes in all three putative CSCs (A549 CD166+/CD44+,
A549 CD166+/EpCAM+, and H2170 CD166+/EpCAM+)
were found to be involved in several biological cancer
processes, including angiogenesis, apoptosis, anti-
apoptosis, induction of apoptosis, cell death, and cell mi-
gration. In addition, the three putative CSCs were found
to share several development and stem cell related bio-
logical processes, such as ectoderm development, epider-
mis development, osteoblast differentiation, mesenchymal
cell development, Wnt receptor signaling, lung develop-
ment, regulation of the NF-kappa β cascade, and bone de-
velopment (Figure 8).
A more informative analysis of functional annotation
was achieved by studying the enrichment of differentially
expressed genes in a particular pathway. The up-regulatedgenes were involved in cancer, ATP-binding cassette
(ABC) transporter, Wnt signaling, drug metabolism, and
NSCLC pathways (Table 6). The significant pathways for
the down-regulated genes were the p53 signaling, apop-
tosis, Hedgehog signaling, ECM-receptor interaction, can-
cer, and SCLC pathways (Table 6).
Discussion
Because CSCs likely play an important role in maintain-
ing cancer cell populations, targeting specific compo-
nents of CSCs regulatory pathways could open up a new
strategy for cancer treatment. Identification and isolation
of CSCs from NSCLC cells is the initial step in identify-
ing more specific CSCs markers in the NSCLC cell
population. We found that CD166 was highly expressed
in both normal and lung cancer cells, and we used the
combinations of CD166/CD44 and CD166/EpCAM for
further analysis.
The flow cytometry analysis revealed that the lung can-
cer cells consist of a heterogeneous population with differ-
ent phenotypes (CD166+/CD44+, CD166+/CD44−, CD166
−/CD44+, CD166−/CD44−, CD166+/EpCAM+, CD166+/Ep
CAM−, CD166−/EpCAM+, and CD166−/EpCAM−), which
supports the initial hypothesis that the CSCs population is
heterogeneous. We hypothesized that the double positive
Figure 5 Analysis of the expression of stem cell related genes in putative CSCs from different cell lines. Detectable expression levels of
the genes were found in all putative CSCs. The PCR reaction without template served as the negative control. The relative expression of target
genes was normalized to the level in the normal lung stem cells. The X-axis shows the target genes and the Y-axis shows the fold change. The
error bars represent the standard deviation within the triplicate experiments.
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putative lung CSCs in A549 and H2170 cells. The putative
lung CSCs showed multilineage differentiation and self-
renewal capability, which proved that they had the stem
cell-like phenotype.
Results of previous studies support the use of CD166,
CD44, and EpCAM as CSCs markers. The combination
of CD166/CD44 was previously used to identify CSCs
from colorectal cancer cell lines; CD166+/CD44+ cells
were found to have higher clonogenicity and accelerated
tumour development compared to CD166−/CD44− cells,
and the observation was cell dependent [33]. To date,
there have been no reports of the combination of CD166/
CD44 and CD166/EpCAM to identify lung CSCs, but co-
expression of other CSCs markers to identify lung CSCs
has been reported. For instance, Wang et al. combined
CD44 and CD90 to identify lung CSCs [22]. They demon-
strated that CD44+/CD90+ cells had therapy resistance and
higher colony and spheroid forming potential when com-
pared to CD44+/CD90−, CD44−/CD90+, and CD44−/CD90−
cells. Another study combined CD133 with CD44 toidentify lung CSCs in A549 cells and found that CD133
+/CD44+ cells had significant CSCs properties (i.e., continu-
ous proliferative capacity and differential potential) [34].
In this study, the expression of surface markers dif-
fered between the tested cell lines, even though both are
NSCLC cell lines. For example, 61.5% and 0.0% of A549
and H2170 cells, respectively, were CD44+. Other studies
using the same A549 cells reported that 84.41% [35] and
0.0% [15] of A549 cells expressed CD44. Stuelten et al.
also found inconsistent expression of CD44 in nine
NSCLC cell lines, including A549 cells [35]. In addition,
different expression levels of CD44 have been reported
in other types of tumours, including colon, ovarian, and
breast cancers [35]. We also found that CD166 and
EpCAM expression differed between cell lines. We de-
tected expression of CD166 in 72.9% and 52.56% of
A549 and H2170 cells, respectively, whereas the values
for EpCAM were 13.8% and 33.8%, respectively. The in-
consistent expression profiles of CSCs markers among
different studies could be related to individual cancer
variations, different potency states, and functional
Figure 6 In vivo tumourigenecity of putative lung CSCs. (A) Xenograft tumour resected from the nude mice. (B) Graft for the tumour growth
experiment. The tumour size was measured using a caliper every two days. The data represent the average value of three animals.
Zakaria et al. BMC Cancer  (2015) 15:84 Page 11 of 16characteristics of the CSCs population. Thus, in the ab-
sence of a specific marker, the true percentage of CSCs
in a tumour, particularly in long-established cancer cell
lines, is controversial [36]. The variation in environ-
mental and selective pressures experienced by cancer
cells in vitro and in vivo might trigger or suppress dif-
ferent pathways that regulate CSCs functions, and it is
not clear whether the CSCs profiles could vary with
circumstances.Table 4 In vivo tumourigenicity experiment of putative
lung CSCs and non-putative CSCs






A549 Parental 20,000 3 / 3 0.89
A549 CD166+/CD44+ 20,000 3 / 3 1.00
A549 CD166−/CD44− 20,000 2 / 3 0.83
A549 CD166+/EpCAM+ 20,000 3 / 3 1.18
A549 CD166−/EpCAM− 20,000 2 / 3 0.70
H2170 Parental 20,000 3 / 3 1.28
H2170 CD166+/EpCAM+ 20,000 3 / 3 1.39
H2170 CD166−/EpCAM− 20,000 2 / 3 0.89
Control (media + matrigel) 20,000 0 / 3 0The abilities of the CD166+/CD44+ and CD166+/EpCAM+
A549 and H2170 cells to differentiate into adipogenic
and osteogenic lineages and to express stem cell tran-
scription factors showed their stem cell characteristics.
Moreover, the increased tumorigenic ability of the puta-
tive lung CSCs as shown in in vivo study also indicated
their cancer stem cells characteristic. Microarray analysis
of putative lung CSCs was carried out to better under-
stand the transcriptomic regulation of putative CSCs as
compared to normal lung stem cells. Using microarray
technology, transcription profiling was performed forTable 5 Number of significantly regulated genes (p < 0.05,
fold change > 2.0) in putative CSCs compared to putative
normal stem cells




1229 598 (48.65%) 631 (51.34%)
A549 CD166+/EpCAM+ vs.
PHBEC CD166+/EpCAM+
1335 677 (50.71%) 658 (49.28%)
H2170 CD166+/ EpCAM+ vs.
PHBEC CD166+/ EpCAM+
1292 547 (42.33%) 745 (57.66%)
Total 3856 1822 2034
Figure 7 Microarray analysis and validation. (A) Volcano plot of differentially expressed genes obtained from microarray analysis. The red
coloured dots represent the differentially expressed genes (fold change > 2, p-value < 0.05). (B) Validation of the microarray data by RT-PCR for six
genes in putative CSCs. Up-regulation of three genes (CDH2, AKT3, and EPHX1) and down-regulation of three genes (ITGA3, THBS1, and LAMC2)
were observed in all cells. (C) Results of the correlation coefficient test between data from the microarray (log2) and RT-PCR (relative to GAPDH)
assays for the genes subjected to the validation study. The X-axis shows the log transformed array data and the Y-axis shows the RT-PCR data for
each sample.
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lines. The composition of the up-regulated genes and their
pathways showed that these genes play an important role
in maintaining the stemness of the lung CSCs, whereas
the dysregulated genes were involved in cellular repair.
The GO term analysis showed consistent results, with
the significantly regulated genes of putative CSCs being
involved in stem cell related biological and development
processes. These findings clearly illustrate that CSCs are
present in lung cancer cells and that these isolated puta-
tive CSCs possess stem cell characteristics.
The significantly regulated genes identified in our
study were involved in the Wnt and hedgehog pathways
and were associated with the self-renewal process ofnormal stem cells [37]. The ability to self-renew is a spe-
cial characteristic of stem cells, as it allows them to div-
ide and maintain their stemness. Wnt and hedgehog
signaling pathways have been reported to play an im-
portant role in carcinogenesis as well as in normal stem
cell processes [4,38]. In addition, the over-expression of
Wnt signaling molecules has been reported to be involved
in drug resistance of A549 cells, and up-regulation of this
signaling pathway was suggested to be one of the charac-
teristics of CSCs [39]. Our microarray data showed that
Wnt signaling was up-regulated only in putative CSCs of
A549 cells; it was not detected in H2170 cells. This could
explain the higher colony forming ability of A549 cells
compared to H2170 cells.
Figure 8 Gene ontology (GO) terms for the biological function of significantly regulated genes from putative CSCs. The level of significance
is represented by the value of fold change.
Zakaria et al. BMC Cancer  (2015) 15:84 Page 13 of 16The ECM interaction pathway is another pathway that
showed a strong relationship with the putative CSCs tran-
scriptome. Our data showed that this pathway was con-
sistently conserved in putative CSCs regardless of cell
type. The ECM is a non-cellular component of cells that
consists of a complex mixture of structural and functional
macromolecules, including proteins, glycoproteins, proteo-
glycans, and polysaccharides. The ECM plays an important
role in tissue and organ morphogenesis and in the mainten-
ance of cell and tissue structure and function [40,41]. In thepresent study, the genes involved in the ECM pathway, in-
cluding laminin and integrins, were down-regulated
(Table 7). It also has been suggested that the ECM is a non-
cellular component of the adult stem cell niche [42,43].
The ECM plays a role in maintaining stem cell properties
and in regulating stem cell differentiation [42,43]. The dys-
regulation of the ECM, which causes an imbalance between
stem cell self-renewal and differentiation, might lead to the
formation of CSCs. In addition, the dysregulation of
ECM was associated with development and progression
Table 6 Common significant pathways associated with up-regulated and down-regulated genes of putative CSCs
Pathway ID Pathways Fold enrichment
A549 CD166+/CD44+ A549 CD166+/EpCAM+ H2170 CD166+/EpCAM+
Up-regulated
hsa00982 Drug metabolism 3.661 – –
hsa02010 ABC transporters 3.041 – –
hsa04010 MAPK signalling pathway – 1.933 1.870
hsa04310 Wnt signalling pathway 1.063 1.025 -
hsa04514 Cell adhesion molecules (CAMs) 1.419 – 1.719
hsa04520 Adherens junction 1.390 – –
hsa05200 Pathways in cancer – 0.944 1.384
hsa05223 Non-small cell lung cancer – 1.912 4.203
Down-regulated
hsa04115 p53 signalling pathway 3.935 2.589 2.660
hsa04210 Apoptosis 1.957 2.783 2.079
hsa04340 Hedgehog signalling pathway 1.737 – –
hsa04512 ECM-receptor interaction 3.765 3.668 3.589
hsa05200 Pathways in cancer 2.225 1.946 1.960
hsa05222 Small cell lung cancer 2.027 2.096 2.392
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ment [44]. An abnormal ECM also indirectly affects
cancer cells by influencing the behavior of stromal cells,
endothelial cells, immune cells, and fibroblasts, which
are the main initial culprits that cause abnormal ECM
production [44-46].
Conclusions
We successfully identified and characterised putative CSCs
from NSCLC cells. The CSCs with the CD166+/CD44+
and CD166+/EpCAM+ phenotypes have the ability to dif-
ferentiate into adipogenic and osteogenic lineages andTable 7 Genes involved in the ECM pathway
Gene
symbol
Gene name Fold change
A549 CD166+/CD44+
ITGA2 Integrin, alpha 2 −6.453101
ITGA3 Integrin, alpha 3 −3.122479
ITGA5 Integrin, alpha 5 −3.526326
ITGA6 Integrin, alpha 6 −3.517541
ITGB4 Integrin, beta 4 −6.819779
ITGB6 Integrin, beta 6 −22.19036
ITGB8 Integrin, beta 8 −5.458705
LAMA3 Laminin, alpha 3 −4.648527
LAMB3 Laminin, beta 3 −8.490638
LAMC2 Laminin, gamma 2 −42.03006
TNC Tenascin C −8.586228
THBS1 Thrombospondin 1 −6.843357possess self-renewal ability. The gene expression study re-
vealed that the putative lung CSC transcriptome is signifi-
cantly associated with stem cells and cancer biological
processes, including angiogenesis, migration, pro-apoptosis
and anti-apoptosis, osteoblast differentiation, mesenchymal
cell differentiation, and mesenchyme development, and is
involved in stem cell self-renewal pathways, Wnt and
hedgehog signaling, and cancer-associated pathways. This
study revealed that isolated putative lung CSCs exhibit the
characteristics of multipotent stem cells, and their genetic
composition might be valuable for future gene and stem
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